MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Type of Mesothelioma:

Loaction of the turmors and cell characteristics are among the differientiating factors in mesothelioma.

Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth.

Oncoimmunology 2018 November 2 [Link] Pappas AG, Magkouta S, Pateras IS, Skianis I, Moschos C, Vazakidou ME, Psarra K, Gorgoulis VG, Kalomenidis I Abstract Versican promotes experimental tumor growth through cell- and non cell-autonomous mechanisms. Its role in mesothelioma progression has not been investigated so far. In this study we investigated the impact of tumor-derived […]

Comments Off on Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth.

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.

BMC Cancer 2019 January 30 [Link] Borchert S1, Wessolly M2, Schmeller J2, Mairinger E, Kollmeier J, Hager T, Mairinger T, Herold T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Aigner C, Schmid KW, Mairinger FD Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a tumour arising from pleural cavities with poor prognosis. Multimodality treatment with pemetrexed combined with cisplatin shows unsatisfying response-rates of 40%. The reasons for the […]

Comments Off on Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.

MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.

BMJ Open Respiratory Research 2019 January 5 [Link] Matthews C, Freeman C, Sharples LD, Fox-Rushby J, Tod A, Maskell NA, Edwards JG, Coonar AS, Sivasothy P, Hughes V, Rahman NM, Waller DA, Rintoul RC Abstract INTRODUCTION: One of the most debilitating symptoms of malignant pleural mesothelioma (MPM) is dyspnoea caused by pleural effusion. MPM can […]

Comments Off on MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.

Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.

European Radiology 2019 January 28 [Link] Halpenny D, Raj M, Rimner A, Zheng J, Capanu M, Ginsberg MS Abstract OBJECTIVE: This study was conducted in order to describe the computed tomography (CT) features of local pleural recurrence in patients with malignant pleural mesothelioma undergoing intensity-modulated pleural radiation therapy (IMPRINT) as part of multimodality treatment. METHODS: […]

Comments Off on Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.

Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.

Biochemical and Biophysical Research Communications 2019 March 5 [Link] Abayasiriwardana KS, Wood MK, Prêle CM, Birnie KA, Robinson BW, Laurent GJ, McAnulty RJ, Mutsaers SE Abstract Malignant mesothelioma is an aggressive fibrous tumor, predominantly of the pleura, with a very poor prognosis. Cell-matrix interactions are recognized important determinants of tumor growth and invasiveness but the […]

Comments Off on Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.

Pretreatment Controlling Nutritional Status Score and Lactate Dehydrogenase as Predictive Markers of Survival in Patients with Malignant Peritoneal Mesothelioma.

Nutrition and Cancer 2019 January 20 [Link] Wang QQ, Zheng GQ, Yang DL, Liang YF, Yin WJ, Su SS Abstract OBJECTIVE: To investigate the relationships between the Controlling Nutritional Status (CONUT) score and ascites fluid lactate dehydrogenase (LDH) level, and prognosis in patients with malignant peritoneal mesothelioma (MPeM). METHODS: A total of 125 patients with […]

Comments Off on Pretreatment Controlling Nutritional Status Score and Lactate Dehydrogenase as Predictive Markers of Survival in Patients with Malignant Peritoneal Mesothelioma.

BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Applied Immunohistochemistry & Molecular Morphology 2019 January 11 [Link] Erber R, Warth A, Muley T, Hartmann A, Herpel E, Agaimy A Abstract Malignant mesothelioma (MM) can show areas closely mimicking reactive mesothelial proliferations or recapitulating benign adenomatoid tumors (ATs) making distinction on occasion impossible on morphologic ground alone, particularly in limited biopsy material. Recently, loss […]

Comments Off on BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial.

Thorax 2019 January 19 [Link] Brims F, Gunatilake S, Lawrie I, Marshall L, Fogg C, Qi C, Creech L, Holtom N, Killick S, Yung B, Cooper D1 Stadon L, Cook P, Fuller E, Walther J, Plunkett C, Bates A, Mackinlay C, Tandon A, Maskell NA, Forbes K, Rahman NM, Gerry S, Chauhan AJ Abstract PURPOSE: […]

Comments Off on Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial.

Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.

Proceedings of the National Academy of Sciences of the United States of America 2019 January 18 [Link] Villanova T, Gesmundo I, Audrito V, Vitale N, Silvagno F, Musuraca C, Righi L, Libener R, Riganti C, Bironzo P, Deaglio S, Papotti M, Cai R, Sha W, Ghigo E, Schally AV, Granata R Abstract Malignant pleural mesothelioma […]

Comments Off on Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.

Prognostic Factors of Survival in Patients with Malignant Pleural Mesothelioma; an analysis of the National Cancer Data Base.

Carcinogenesis; 2019 January 10 [Link] van Gerwen M, Alpert N, Wolf A, Ohri N, Lewis E, Rosenzweig KE, Flores R, Taioli E Abstract Malignant pleural mesothelioma is a rare disease with a very poor prognosis. Previous studies have indicated that women experience longer survival compared to men. We analyzed 16,267 eligible patients (21.3% females) in […]

Comments Off on Prognostic Factors of Survival in Patients with Malignant Pleural Mesothelioma; an analysis of the National Cancer Data Base.